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Introduction
Thoracic surgical presentation of patients with advanced 
parapneumonic pleural empyema is often delayed due to 
late diagnosis and inconsequent antibiotic therapy of the 
underlying pneumonia (1). Hence, the optimal moment 
is missed for a minimal invasive procedure providing 
a relevant input of infection control (2,3). Length of 
antibiotic treatment or bacterial spectrum is often 
unknown. Pleural enhancement andand pleural thickening, 
fibrin septa and a trapped lung are the typical findings in 
computer tomography (CT) scan and sonography. Patients 
with pleural empyema show the clinical signs of infections 
consisting of fever, chest pain, dyspnea, leukocytosis and 
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infection. In contrast, the blood marker procalcitonin (PCT) 
has been successfully introduced as a marker for guidance of 
antibiotic therapy in lower respiratory tract infections (6,7). 
It correlates with severity and extent of bacterial infections 
and is only increased in systemic infections like pneumonia. 
In localized processes like empyema PCT-levels are usually 
not elevated. Thus, falling preoperative PCT (pPCT)-levels 
may be useful to evaluate a successful systemic treatment 
and are therefore a good precondition for major surgery (8). 
The aim of this retrospective study is to evaluate PCT as a 
preoperative marker in advanced parapneumonic empyema. 
We hypothesize a shorter postoperative length of stay and 
fewer complications when the surgical intervention takes 
place once PCT levels have dropped to normal ranges 
compared to early interventions with increased PCT levels.
Methods
Subjects and study design 
This is a retrospective observational study at the Cantonal 
Hospital Aarau, Switzerland. Between June 2010 and April 
2015, 38 consecutive patients were operated on for advanced 
parapneumonic pleural empyema and are included in this 
analysis. We did not consider patients with other than 
parapneumonic empyemas (i.e., traumatic, postoperative). 
This study was conducted in accordance with the amended 
Declaration of Helsinki. Local ethic committee (EKNZ 
2014-401) approved the protocol and informed consent was 
obtained from all patients. 
Definitions
Initial diagnosis of pneumonia was related to clinical signs 
such as cough, chest pain, infiltrate on chest X-ray and no 
other sources for infection. The consecutive complicated 
pleural effusion was therefore diagnosed as parapneumonic. 
Definition of pleural empyema was based on clinical 
course after initialization of antibiotic treatment because of 
pneumonia and typical radiographic features in computer 
tomography scans (Figures 1,2). Diagnosis of advanced 
stage was done preoperatively due to the CT scan and was 
confirmed intra-operatively. According to the American 
Thoracic Society, advanced or stage III empyemas are 
defined as empyemas that show a loss of lung compliance 
due to fibrous peel, completely entrapping the parenchyma 
(Figure 3). Once the preoperative diagnosis of an advanced 
empyema was defined, patients were scheduled for surgery 
Figure 1 Typical chest X-ray of advanced parapneumonic empyema 
on the right side.
Figure 2 Computer tomography of the same patient as in Figure 1.
elevation of C-reactive protein. Under the mentioned 
circumstances a surgical procedure is intended to free 
the trapped lung enabling a normal lung function rather 
than providing a rapid infection control. Based on these 
requirements strictly minimal invasive procedures are 
not sufficient enough and therefore at least partial open 
procedures such as decortication and/or pleurectomy are 
needed (4,5). Stable condition of patients and extent of 
surgical procedure do not necessitate an operative urgency 
comparable to early empyema and allow for that reason the 
best possible preparation to major surgery. This consists in 
consequent antibiotic treatment of the systemic infection 
and—if necessary—in the drainage of relevant liquid 
portions. To evaluate the success of systemic treatment, 
white blood cells (WBC) and C-reactive protein (CRP) 
are not appropriate enough neither to recognize bacterial 
infections nor to distinguish between systemic and local 
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Figure 3 Intraoperative situs of the same patient as in Figures 1,2, 
presenting parapneumonic empyema stage III. Thoracotomy 
shows the extra-pleural dissected empyema.
Figure 4 Chest X-ray of the same patient as in Figures 1-3, 
performed 6 weeks postoperatively.
as soon as possible in accordance to the OR during the 
daily working time within the next days. There were no 
emergency operations. PCT values were obtained the day 
before surgery.
PCT cut-offs and surgical procedure
We identified 38 patients with available pPCT values who 
were assigned to two groups according to the PCT cut-
off of 0.25 μg/L. This cut-off was chosen according to 
the ProHOSP study group (9). pPCT blood levels were 
routinely obtained the day before the scheduled surgery. 
All operations were performed by the same two thoracic 
surgeons. The main goal of every operation was complete 
pulmonary re-expansion. All operations were performed 
as an open decortication and pleurectomy. The procedure 
was performed with a lateral muscle-sparing thoracotomy 
in the sixth intercostal space with preservation of both the 
latissimus dorsi and the serratus anterior muscles. The 
operation consisted of complete removal of the fibrous peel 
trapping the lung and of resection of the parietal peel by an 
extra-pleural dissection. Two chest tubes were placed and 
the preoperatively started antibiotics were continued. 
We retrospectively analyzed the following clinical 
variables: age, sex, preoperative CRP, preoperative WBC, 
pPCT, initial PCT at admission (if available), comorbidities, 
postoperative 30-day morbidity, postoperative 30-day 
mortality, postoperative and overall length of stay and 
CRP the day before hospital discharge, length of stay from 
admission to operation.
Chest roentgenograms 1 to 3 months postoperatively 
(Figure 4) were compared with the preoperative roentgenograms 
(Figure 1) and the radiological improvement was calculated 
using a 5-point percentage scale according to Casali et al. 
(5,10). Complete re-expansion (100%) and moderate 
improvement (75%) were considered as satisfactory results. 
The radiological estimation was conducted independently 
by two of the authors (C Caviezel and F Gambazzi) and the 
mean result of the observations was used for the analysis.
Statistics
The primary endpoint of this analysis was all total length 
of hospital stay within the index hospitalization and 
postoperative length of stay. Secondary endpoints included 
serious adverse events defined as death or surgery-related 
complications.
Discrete variables are expressed as counts (percentage) 
and continuous variables as medians and interquartile 
ranges (IQR). Frequency comparison was done using the 
chi-square test. The two-group comparison for continuous 
data was done with the students t-test. We used univariate 
and multivariate regression analysis to study the association 
between PCT level and primary and secondary outcomes 
adjusting the models for important confounding factors 
such as age, gender and comorbidities. Logarithmic 
transformation of non-normally distributed data was done 
prior to modeling (length of stay). Area under the receiver-
operating-characteristics curve (AUC) was calculated to 
assess overall discrimination using STATA 9.2 (Stata Corp, 
College Station, Texas, USA). All statistical tests were 
two-tailed and P values less than 0.05 were considered to 
indicate statistical significance.
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Table 1 Baseline and outcome data of the patients stratified based on PCT levels <0.25 and ≥0.25 μg/L
Patients PCT <0.25 PCT ≥0.25 P value
N 17 21
Demographics
Age, median (IQR) 63 (49, 67) 65 (48, 76) 0.22
Male gender 13 (76%) 13 (62%) 0.34
Comorbidities 
Asthma bronchiale 0 (0%) 2 (10%) 0.19
Chronic renal failure 0 (0%) 5 (24%) 0.031
COPD 0 (0%) 1 (5%) 0.36
Diabetes mellitus type II 1 (6%) 3 (14%) 0.40
Heart disease 2 (12%) 9 (43%) 0.036
Hypertension 3 (18%) 5 (24%) 0.64
Obesity 2 (12%) 2 (10%) 0.82
Rheumatoid arthritis (steroid treatment) 1 (6%) 1 (5%) 0.88
Blood levels before surgery 
WBC, median (IQR) 9.355 (7.74, 12.36) 12.28 (10.25, 20.56) 0.015
PCT, median (IQR) 0.13 (0.11, 0.18) 1.06 (0.46, 2.81) <0.001
CRP, median (IQR) 132 (50, 176) 186 (144, 272) 0.005
Outcome data
CRP at discharge, median (IQR) 48 (30, 69) 64 (21, 119) 0.58
Length of hospital stay, median (IQR) 15 (10, 21) 22.4 (16, 28) 0.009
Any complications 0 (0%) 8 (38%) 0.004
Types of complications   
Acute cholecystitis, hemorrhagic pericardial effusion 0 (0%) 1 (13%)
Critical illness neuromyopathy, upper GI-bleeding 0 (0%) 1 (13%)
Recurrent empyema with re-thoracotomy 0 (0%) 1 (13%)
Exitus letalis 0 (0%) 1 (13%)
Exitus letalis 0 (0%) 1 (13%)
Hematothorax with re-thoracotomy 0 (0%) 1 (13%)
Wound infection 0 (0%) 1 (13%)
Congestive heart failure 0 (0%) 1 (13%)
PCT, procalcitonin; IQR, interquartile range; COPD, chronic obstructive pulmonary disease; WBC, white blood cells; CRP, C-reactive protein.
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Results
Patient population
A total of 38 patients were included in this analysis with a 
median age of 64 years and 16 patients being males. Patients 
had a high burden of comorbidities including heart disease 
in 29%, diabetes in 10.5% and chronic renal failure in 13%. 
The median overall hospital stay was 17 days. Surgery-related 
complications occurred in 21% and mortality was 5.25%.
Thirty-four of the 38 patients had a satisfactory radiological 
improvement after decortication and pleurectomy (89%). 
In 13 patients (34%) the improvement was moderate and in 
21 patients (55%) there was complete re-expansion of the 
lung.
PCT was measured preoperatively and these patients 
were divided into two groups based on the pPCT level at 
the 0.25 μg/L cut-off. Table 1 shows baseline and outcome 
data of the patients stratified based on their PCT levels 
<0.25 and ≥0.25 μg/L. The two populations were similar 
but showed significant differences in regard to chronic 
renal failure and heart disease. The median preoperative 
CRP levels were 132 mg/L (IQR 50–176) in the <0.25 μg/L 
group and 186 mg/L (IQR 144–272) in the ≥0.25 μg/L 
group (P=0.005). For WBC, the respective median values 
were 9.4 G/l (IQR 7.7–12.4) and 12.3 G/l (IQR 10.3–20.6) 
(P=0.015).
Association of initial PCT level at admission and of pPCT 
level
PCT level at admission was available in 28 patients. In 
these patients median initial PCT level was 2.25 μg/L (IQR 
1–9.6) and dropped preoperatively to 0.445 μg/L (IQR 
0.1–1, P<0.001). Patients with a pPCT level <0.25 μg/L 
(12/28) had a drop from initially 2.25 to 0.1 μg/L (P=0.002). 
Patients with a pPCT level ≥0.25 μg/L (16/28) had a drop 
from initially 2.36 to 0.99 μg/L (P=0.004). Initial PCT 
levels show no significant difference between the two 
groups (P=0.695). 
Length of stay from admission to operation
Mean length of stay from admission to operation for all 
patients [38] was 5.8 days (IQR 2–8, range 1–15). Patients 
with a pPCT level <0.25 μg/L had a mean preoperative stay 
of 6.2 days (IQR 2–9.5). Patients with pPCT level ≥0.25 μg/L 
had almost the same preoperative length of stay (median 
5.4 days, IQR 2.5–7, P=0.66). 
Association of pPCT level and outcomes
pPCT levels were available in all patients. Patients with 
a pPCT level ≥0.25 μg/L had a significantly longer total 
length of hospital stay [mean 22.4 vs. 15.0 days, difference 
−7.4 days (95% CI: −12.8 to −2.0), P=0.009]. This was also 
confirmed in linear regression analysis with an adjusted 
regression coefficient for log-transformed length of stay of 
−0.34 (95% CI: −0.10 to −0.58, P=0.008) when adjusting for 
age and gender and regression coefficient of −0.27 (95% CI: 
−0.02 to −0.52, P=0.037) after adjusting for age, gender and 
comorbidities. Results were similar for time from surgery 
to discharge (17.0 vs. 8.7 days, difference −8.2 days, 95% 
CI: −12.5 to −4.0, P<0.001) with again significant results in 
adjusted regression analysis [regression coefficient of −0.55 
(95% CI: −0.29 to −0.81, P<0.001] after adjusting for age 
and gender and −0.48 (95%CI: −0.23 to −0.74, P=0.001) 
after adjusting for age, gender and comorbidities (Figure 5).
Overall, eight patients had postoperative complications, 
two of them died (mortality 5.25%). All complications 
occurred in patients with a pPCT level ≥0.25 μg/L (38% 
vs. 0%, P=0.004). We also compared CRP levels prior to 
hospital discharge between the two groups but did not find 
any significant difference (difference −19.8, 95% CI: −60.2 
to 20.7, P=0.32).
Discussion
Surgical treatment of advanced parapneumonic empyema is 
widely accepted [14]. There is current literature focusing on 
minimal-invasive thoracic surgery and on the identification of 
clinical predictors to operate successfully with thoracoscopic 
surgery to avoid thoracotomy and therefore major thoracic 
Figure 5 Association of preoperative PCT level and length of 
hospital stay. PCT, procalcitonin.
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surgery (5,11,12). However, advanced parapneumonic 
empyema still often needs thoracotomy for complete 
pleural decortication (4,5,13,14). Current literature quotes 
a mean postoperative length of stay between 8 and 20 days 
in cases of thoracotomy due to empyema. Postoperative 
morbidity ranges from 11% to 42% (2-5,15). Therefore, 
parapneumonic empyema is a disease with a high burden 
for the patient and the most appropriate therapy has to 
be selected as early as possible to decrease delay between 
diagnosis and surgery. Although nowadays early surgery is 
generally advised one should respect the patient’s recovering 
from pneumonia prior to the operation. PCT has been 
recently successfully introduced as a clinical marker for 
guiding antibiotic therapy in community-acquired pneumonia 
(8,9). In our retrospective study we analyzed 38 patients 
with parapneumonic empyema stage who needed 
thoracotomy for open decortication. The mean length 
of stay was postoperative 12.8 days and overall 18.7 days. 
These data are comparable with the current literature 
(2,3,5,14). Complications occurred in 21%, mortality was 
5.25%, whereas the first is also well comparable with the 
values in literature, the second one is slightly lower. 
All operations were performed by the same two thoracic 
surgeons which ensure some consistency of quality. 
Fifty-five percent of all patients presented complete 
radiological re-expansion of the lung and 34 % presented 
moderate improvement. The radiological result is one 
of the only measurable indicators regarding quality after 
lung decortication besides complications and length of 
stay. Only performing decortication in chronic empyema 
(after a certain interval between empyema detection and 
surgery) may lung function tests make feasible. Bagheri 
and colleagues operated after a median of 63.25 days and 
showed significant improved postoperative pulmonary 
function (16). 
Our measured CRP prior to hospital discharge (mean 
value 72 mg/L) reflects the usual course postoperatively (13) 
and did not significantly differ between the two pPCT 
groups.
The group with a pPCT <0.25 μg/L showed a significant 
better outcome than the group with pPCT ≥0.25 μg/L. 
The first group had a shorter overall and postoperative 
length of stay and no occurrence of either complications or 
mortality. This finding reinforces our approach of operating 
on patients presenting with advanced empyema as recently 
as they have completely recovered from pneumonia. 
Carboni et al. analyzed postoperative PCT with CRP 
after decortication of 17 parapneumonic and 5 traumatic 
empyemas (13). Two groups were compared, one with septic 
signs and one without septic signs postoperatively. The first 
group had higher PCT levels and higher CRP levels on 
postoperative days 1 and 7. Interestingly, the first group had 
a median PCT level of 0.29 μg/L preoperatively, whereas 
the second group a mean value of 0.12 μg/L. Further 
information than measured values until postoperative 
day 7 (i.e., length of hospital stay) are not available. 
These findings might confirm our hypothesis of a higher 
postoperative complication rate when parapneumonic 
empyema is operated on before PCT values have dropped. 
In 28 patients initial PCT levels at time of admission to 
the hospital were known. There is no significant difference 
between the two groups but both groups show a significant 
PCT drop during the preoperative length of stay. Both 
groups had no significant difference in preoperative length 
of stay. As the pPCT ≥0.25 μg/L group had significantly 
more postoperative complications we assume a prolonged 
preoperative waiting time would have been justified to reach 
pPCT levels <0.25 μg/L.
Regarding the preoperative CRP and WBC values there 
is a significant difference between the two groups with the 
higher values in the pPCT ≥0.25 μg/L group. Like the 
elevated PCT we interpret these results as another effect 
of ongoing pneumonia but regard CRP and WBC as less 
specific markers for bacterial infections (17).
Besides the small number of patients the study’s 
retrospective manner is a clear limitation. In addition, 
it has always been the division’s approach to postpone 
empyema surgery in favor of a medically fitter patient 
using clinical signs. Since PCT is not routinely provided 
in our commuting area we do not know the development 
of PCT from the time of diagnosis of pneumonia until 
presentation to our division. Based on the numerous studies 
about pneumonia and PCT we assume that almost all of 
our patients had initially an even more elevated PCT due 
to pneumonia and therefore this bias might be of minimal 
matter. The exact onset of treatment before admission 
to our hospital was not taken into account in this study 
and therefore the exact length of antibiotic therapy is not 
considered, either. When early surgical management of 
parapneumonic empyema is discussed in literature, there 
are delays in operation between 5 and 92 days (5) and some 
authors confirmed a better outcome when the operation was 
performed within 11 days of admission (11). In our case, 
the 38 patients had a mean stay of 5.8 days before operation 
(range, 1–15) which is justified especially if initial PCT 
would be ≥0.25 μg/L. Another limitation is the restriction 
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to surgically treated patients. Therefor the natural course 
of PCT in non-operatively managed empyema patients is 
not known. Neither the course of patients with early stage 
empyema and possibly minimal-invasively operated patients 
is taken into account. 
Nevertheless, the time from diagnosis of parapneumonic 
empyema and reaching pPCT levels <0.25 μg/L under 
antibiotic treatment until final operation has to be shortened. 
Therefore, the initially declared dogma of early aggressive 
surgical management should only be advised when the 
patient’s condition has improved due to decay of pneumonia. 
One might question the operation itself considering these 
favorable results regarding control of infection. Although the 
main goal of decortication is curing the restrictive disease, 
there is no doubt that decortication in parapneumonic 
empyema inhibits recurrent empyema by completing control 
of (chronic) infection (18). High preoperative CRP and 
WBC levels confirm persistent local inflammation despite 
decreased SIRS due to cured pulmonary parenchyma 
invading pneumonia. This interpretation focuses on advanced 
parapneumonic empyema where open decortication is 
foreseen. Early stages still profit from thoracoscopic drainage 
as early as possible (1-3,19).
To our knowledge this is the first report on PCT as a 
possible marker for the timing of decortication in advanced 
parapneumonic empyema. It favors the continuation of 
antibiotic therapy until pPCT decreases to <0.25 μg/L. 
Therefore, the main goals of therapy in advanced 
parapneumonic empyema must be the treatment of 
pneumonia with antibiotics followed by correcting the 
restrictive disease and preventing chronic infection with 
decortication and pleurectomy. These results encourage us to 
conduct a prospective trial regarding timing of decortication.
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